Skip to main content

Table 8 Incremental cost-effectiveness ratio of PEMF vs. standard treatment for acute scaphoid fractures

From: Functional outcome and cost-effectiveness of pulsed electromagnetic fields in the treatment of acute scaphoid fractures: a cost-utility analysis

  Costs* QALY ICER
Group A (Active) €2827 0.84  
Group B (Placebo) €2253 0.8545  
Increment €574 -0.0145 inferior
  1. *Costs are denoted in Euro.
  2. QALY, quality adjusted life year; ICER, incremental cost-effectiveness ratio.